CERTL reduces C16 ceramide, amyloid-β levels, and inflammation in a model of Alzheimer’s disease

[1]  Zhihui Zhu,et al.  Association of Aβ with ceramide-enriched astrosomes mediates Aβ neurotoxicity , 2020, Acta Neuropathologica Communications.

[2]  Concomitant , 2020, Definitions.

[3]  H. D. de Vries,et al.  Sphingolipids in Alzheimer's disease, how can we target them? , 2020, Advanced drug delivery reviews.

[4]  A. V. D. van der Steen,et al.  Variation in Coronary Atherosclerosis Severity Related to a Distinct LDL (Low-Density Lipoprotein) Profile , 2019, Arteriosclerosis, thrombosis, and vascular biology.

[5]  H. D. de Vries,et al.  Astrocytic ceramide as possible indicator of neuroinflammation , 2019, Journal of Neuroinflammation.

[6]  H. Morrison,et al.  Quantifying Microglia Morphology from Photomicrographs of Immunohistochemistry Prepared Tissue Using ImageJ , 2018, Journal of visualized experiments : JoVE.

[7]  F. Foufelle,et al.  Ceramide Transporter CERT Is Involved in Muscle Insulin Signaling Defects Under Lipotoxic Conditions , 2018, Diabetes.

[8]  F. Bai,et al.  LINGO‐1 antibody ameliorates myelin impairment and spatial memory deficits in the early stage of 5XFAD mice , 2018, CNS neuroscience & therapeutics.

[9]  Zhijun Zhang,et al.  Myelin changes at the early stage of 5XFAD mice , 2018, Brain Research Bulletin.

[10]  E. Bieberich,et al.  Neutral Sphingomyelinase-2 Deficiency Ameliorates Alzheimer's Disease Pathology and Improves Cognition in the 5XFAD Mouse , 2016, The Journal of Neuroscience.

[11]  Burkhard Becher,et al.  Immune attack: the role of inflammation in Alzheimer disease , 2015, Nature Reviews Neuroscience.

[12]  R. Ransohoff,et al.  Nuclear Receptors License Phagocytosis by Trem2+ Myeloid Cells in Mouse Models of Alzheimer's Disease , 2015, The Journal of Neuroscience.

[13]  Takeshi Iwatsubo,et al.  Synthetic ceramide analogues increase amyloid-β 42 production by modulating γ-secretase activity. , 2015, Biochemical and biophysical research communications.

[14]  F. Edwards,et al.  A genome-wide gene-expression analysis and database in transgenic mice during development of amyloid or tau pathology. , 2015, Cell reports.

[15]  Henry Pinkard,et al.  Advanced methods of microscope control using μManager software. , 2014, Journal of biological methods.

[16]  I. Ferrer,et al.  Altered lipid composition in cortical lipid rafts occurs at early stages of sporadic Alzheimer's disease and facilitates APP/BACE1 interactions , 2014, Neurobiology of Aging.

[17]  E. Bieberich,et al.  Exosome reduction in vivo is associated with lower amyloid plaque load in the 5XFAD mouse model of Alzheimer's disease , 2014, Neurobiology of Aging.

[18]  F. Roman,et al.  Onset of hippocampus‐dependent memory impairments in 5XFAD transgenic mouse model of Alzheimer's disease , 2014, Hippocampus.

[19]  A. Dhanushkodi,et al.  Abnormal vibrissa‐related behavior and loss of barrel field inhibitory neurons in 5xFAD transgenics , 2014, Genes, brain, and behavior.

[20]  T. Yamaji,et al.  Establishment of HeLa Cell Mutants Deficient in Sphingolipid-Related Genes Using TALENs , 2014, PloS one.

[21]  H. Steinbusch,et al.  Complement Activation by Ceramide Transporter Proteins , 2014, The Journal of Immunology.

[22]  K. Hanada,et al.  A novel inhibitor of ceramide trafficking from endoplasmic reticulum to the site of sphingomyelin synthesis. , 2013, The Journal of Biological Chemistry.

[23]  J. Degen,et al.  Inactivation of Ceramide Synthase 6 in Mice Results in an Altered Sphingolipid Metabolism and Behavioral Abnormalities* , 2013, The Journal of Biological Chemistry.

[24]  F. Heppner,et al.  Functional Impairment of Microglia Coincides with Beta-Amyloid Deposition in Mice with Alzheimer-Like Pathology , 2013, PloS one.

[25]  Christopher Exley,et al.  Copper prevents amyloid-β1–42 from forming amyloid fibrils under near-physiological conditions in vitro , 2013, Scientific Reports.

[26]  H. Steinbusch,et al.  Behavioral and neurobiological effects of prenatal stress exposure in male and female APPswe/PS1dE9 mice , 2013, Neurobiology of Aging.

[27]  A. Hofman,et al.  Variant of TREM2 associated with the risk of Alzheimer's disease. , 2013, The New England journal of medicine.

[28]  C. Lyketsos,et al.  Serum ceramides increase the risk of Alzheimer disease , 2012, Neurology.

[29]  M. Jensen,et al.  A liquid chromatography/tandem mass spectrometry method for measuring the in vivo incorporation of plasma free fatty acids into intramyocellular ceramides in humans. , 2012, Rapid communications in mass spectrometry : RCM.

[30]  Y. Hannun,et al.  Safety study of adeno-associated virus serotype 2-mediated human acid sphingomyelinase expression in the nonhuman primate brain. , 2012, Human Gene Therapy.

[31]  Erhard Bieberich,et al.  Astrocytes Secrete Exosomes Enriched with Proapoptotic Ceramide and Prostate Apoptosis Response 4 (PAR-4) , 2012, The Journal of Biological Chemistry.

[32]  R. Veerhuis,et al.  Goodpasture Antigen-binding Protein/Ceramide Transporter Binds to Human Serum Amyloid P-Component and Is Present in Brain Amyloid Plaques* , 2012, The Journal of Biological Chemistry.

[33]  Oliver Wirths,et al.  Motor deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and intraneuronal Aβ aggregation in the 5XFAD mouse model of Alzheimer's disease , 2012, Neurobiology of Aging.

[34]  S. Ingrand,et al.  Ceramide and Related-Sphingolipid Levels Are Not Altered in Disease-Associated Brain Regions of APPSL and APPSL/PS1M146L Mouse Models of Alzheimer's Disease: Relationship with the Lack of Neurodegeneration? , 2010, International journal of Alzheimer's disease.

[35]  M. D. de Baets,et al.  The ceramide transporter and the Goodpasture antigen binding protein: one protein – one function? , 2010, Journal of neurochemistry.

[36]  A. Verkhratsky,et al.  Concomitant astroglial atrophy and astrogliosis in a triple transgenic animal model of Alzheimer's disease , 2010, Glia.

[37]  M. Ohno,et al.  Partial reduction of BACE1 improves synaptic plasticity, recent and remote memories in Alzheimer’s disease transgenic mice , 2010, Journal of neurochemistry.

[38]  C. Gong,et al.  Deregulation of sphingolipid metabolism in Alzheimer's disease , 2010, Neurobiology of Aging.

[39]  Y. Terayama,et al.  Levels of reduced and oxidized coenzyme Q-10 and 8-hydroxy-2′-deoxyguanosine in the CSF of patients with Alzheimer’s disease demonstrate that mitochondrial oxidative damage and/or oxidative DNA damage contributes to the neurodegenerative process , 2010, Journal of Neurology.

[40]  J. Degen,et al.  Adult Ceramide Synthase 2 (CERS2)-deficient Mice Exhibit Myelin Sheath Defects, Cerebellar Degeneration, and Hepatocarcinomas* , 2009, The Journal of Biological Chemistry.

[41]  Y. Hannun,et al.  Bioactive sphingolipids: metabolism and function This work was supported by National Institutes of Health Grants GM-43825 and CA-87584. Published, JLR Papers in Press, November 17, 2008. , 2009, Journal of Lipid Research.

[42]  J. Acharya,et al.  Mitochondrial degeneration and not apoptosis is the primary cause of embryonic lethality in ceramide transfer protein mutant mice , 2009, The Journal of cell biology.

[43]  E. Koo,et al.  Amyloid Precursor Protein Trafficking, Processing, and Function* , 2008, Journal of Biological Chemistry.

[44]  P. Martinez-Martinez,et al.  Goodpasture Antigen-binding Protein Is a Soluble Exportable Protein That Interacts with Type IV Collagen , 2008, Journal of Biological Chemistry.

[45]  Thomas D. Schmittgen,et al.  Analyzing real-time PCR data by the comparative CT method , 2008, Nature Protocols.

[46]  E. Bieberich,et al.  Long‐chain ceramide is elevated in presenilin 1 (PS1M146V) mouse brain and induces apoptosis in PS1 astrocytes , 2008, Glia.

[47]  Yusuf A. Hannun,et al.  Principles of bioactive lipid signalling: lessons from sphingolipids , 2008, Nature Reviews Molecular Cell Biology.

[48]  M. Ohno,et al.  BACE1 gene deletion prevents neuron loss and memory deficits in 5XFAD APP/PS1 transgenic mice , 2007, Neurobiology of Disease.

[49]  V. Haroutunian,et al.  Gene Expression Alterations in the Sphingolipid Metabolism Pathways during Progression of Dementia and Alzheimer’s Disease: A Shift Toward Ceramide Accumulation at the Earliest Recognizable Stages of Alzheimer’s Disease? , 2007, Neurochemical Research.

[50]  M. Ohno,et al.  Intraneuronal β-Amyloid Aggregates, Neurodegeneration, and Neuron Loss in Transgenic Mice with Five Familial Alzheimer's Disease Mutations: Potential Factors in Amyloid Plaque Formation , 2006, The Journal of Neuroscience.

[51]  T. Steckler,et al.  Transgenic Mice Overexpressing Glycogen Synthase Kinase 3β: A Putative Model of Hyperactivity and Mania , 2006, The Journal of Neuroscience.

[52]  B. Kriem,et al.  Soluble oligomers of amyloid-β peptide induce neuronal apoptosis by activating a cPLA2-dependent sphingomyelinase-ceramide pathway , 2006, Neurobiology of Disease.

[53]  Liana C. Silva,et al.  Ceramide-platform formation and -induced biophysical changes in a fluid phospholipid membrane , 2006, Molecular membrane biology.

[54]  I. López-Montero,et al.  Rapid Transbilayer Movement of Ceramides in Phospholipid Vesicles and in Human Erythrocytes* , 2005, Journal of Biological Chemistry.

[55]  S. Yasuda,et al.  CERT Mediates Intermembrane Transfer of Various Molecular Species of Ceramides* , 2005, Journal of Biological Chemistry.

[56]  B. Penke,et al.  Amyloid β‐peptide interactions with neuronal and glial cell plasma membrane: binding sites and implications for Alzheimer's disease , 2004 .

[57]  M. Mattson,et al.  Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[58]  Xianlin Han,et al.  Amyloid-β peptide induces oligodendrocyte death by activating the neutral sphingomyelinase–ceramide pathway , 2004, The Journal of Cell Biology.

[59]  Satoshi Yasuda,et al.  Molecular machinery for non-vesicular trafficking of ceramide , 2003, Nature.

[60]  S. Kügler,et al.  Differential transgene expression in brain cells in vivo and in vitro from AAV-2 vectors with small transcriptional control units. , 2003, Virology.

[61]  L. Puglielli,et al.  Withdrawal: Ceramide stabilizes β-site amyloid precursor protein-cleaving enzyme 1 and promotes amyloid β-peptide biogenesis , 2003, Journal of Biological Chemistry.

[62]  G. Westmeyer,et al.  Identification of a β-Secretase Activity, Which Truncates Amyloid β-Peptide after Its Presenilin-dependent Generation* , 2003, The Journal of Biological Chemistry.

[63]  B. Hyman,et al.  Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease. , 2002, Archives of neurology.

[64]  Xianlin Han,et al.  Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease pathogenesis , 2002, Journal of neurochemistry.

[65]  Y. Imai,et al.  Macrophage/Microglia-specific Protein Iba1 Enhances Membrane Ruffling and Rac Activation via Phospholipase C-γ-dependent Pathway* , 2002, The Journal of Biological Chemistry.

[66]  S. Yasuda,et al.  A Novel Inhibitor of Ceramide Trafficking from the Endoplasmic Reticulum to the Site of Sphingomyelin Synthesis* , 2001, The Journal of Biological Chemistry.

[67]  George Paxinos,et al.  The Mouse Brain in Stereotaxic Coordinates , 2001 .

[68]  G. van Meer,et al.  Sphingolipid transport in eukaryotic cells. , 2000, Biochimica et biophysica acta.

[69]  B. Strooper,et al.  Proteolytic processing and cell biological functions of the amyloid precursor protein. , 2000, Journal of cell science.

[70]  Y. Hannun,et al.  The role of ceramide in cell signaling. , 1998, Biochimica et biophysica acta.

[71]  N. Christophidis,et al.  Serum interleukin-6 and interleukin-6 soluble receptor in Alzheimer's disease , 1998, Neuroscience Letters.

[72]  A. Futerman,et al.  Distinct Roles for Ceramide and Glucosylceramide at Different Stages of Neuronal Growth , 1997, The Journal of Neuroscience.

[73]  M. Hüll.  Interleukin-6-Associated Inflammatory Processes in Alzheimer's Disease: New Therapeutic Options , 1996 .

[74]  C. Masters,et al.  Regulation of Amyloid Protein Precursor (APP) Binding to Collagen and Mapping of the Binding Sites on APP and Collagen Type I (*) , 1996, The Journal of Biological Chemistry.

[75]  Paul L. Wood,et al.  Cytokine indices in Alzheimer's temporal cortex: no changes in mature IL-1β or IL-1RA but increases in the associated acute phase proteins IL-6, α2-macroglobulin and C-reactive protein , 1993, Brain Research.

[76]  A. Rees,et al.  Molecular cloning of the human Goodpasture antigen demonstrates it to be the alpha 3 chain of type IV collagen. , 1992, The Journal of clinical investigation.

[77]  S. Spiegel,et al.  Sphingosine-1-phosphate, a novel lipid, involved in cellular proliferation , 1991, The Journal of cell biology.

[78]  M. Dichter,et al.  Electrophysiological comparison of pyramidal and stellate nonpyramidal neurons in dissociated cell culture of rat hippocampus , 1991, Brain Research Bulletin.

[79]  B. Anderton,et al.  Beta amyloid precursor protein mediates neuronal cell‐cell and cell‐surface adhesion , 1991, Journal of neuroscience research.

[80]  S. Murayama,et al.  Neurofibrillary tangles in human upper cervical ganglia , 1987, Acta Neuropathologica.

[81]  J. Morrison,et al.  Quantitative morphology and regional and laminar distributions of senile plaques in Alzheimer's disease , 1985, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[82]  H. Wiśniewski,et al.  Evidence for Blood‐Brain Barrier Changes in Senile Dementia of the Alzheimer Type (SDAT) , 1982, Annals of the New York Academy of Sciences.

[83]  A. Harvey,et al.  Small Scale Production of Recombinant Adeno-Associated Viral Vectors for Gene Delivery to the Nervous System. , 2018, Methods in molecular biology.

[84]  J. Kwok,et al.  Age-Dependent Changes to Sphingolipid Balance in the Human Hippocampus are Gender-Specific and May Sensitize to Neurodegeneration. , 2018, Journal of Alzheimer's disease : JAD.

[85]  H. D. de Vries,et al.  Altered Sphingolipid Balance in Capillary Cerebral Amyloid Angiopathy. , 2017, Journal of Alzheimer's disease : JAD.

[86]  F. Mottaghy,et al.  Synthesis, Radiosynthesis, and Preliminary in vitro and in vivo Evaluation of the Fluorinated Ceramide Trafficking Inhibitor (HPA-12) for Brain Applications. , 2017, Journal of Alzheimer's disease : JAD.

[87]  T. Bayer,et al.  Gene Dosage Dependent Aggravation of the Neurological Phenotype in the 5XFAD Mouse Model of Alzheimer's Disease. , 2015, Journal of Alzheimer's disease : JAD.

[88]  S. Gras,et al.  Transmission electron microscopy of amyloid fibrils. , 2011, Methods in molecular biology.

[89]  V. Sapira,et al.  Study of interleukin-6 production in Alzheimer's disease. , 2011, Romanian journal of internal medicine = Revue roumaine de medecine interne.

[90]  E. Gulbins,et al.  Ceramide-enriched membrane domains--structure and function. , 2009, Biochimica et biophysica acta.

[91]  Christopher Exley,et al.  Aluminium, iron, zinc and copper influence the in vitro formation of amyloid fibrils of Abeta42 in a manner which may have consequences for metal chelation therapy in Alzheimer's disease. , 2004, Journal of Alzheimer's disease : JAD.

[92]  B. Penke,et al.  Amyloid beta-peptide interactions with neuronal and glial cell plasma membrane: binding sites and implications for Alzheimer's disease. , 2004, Journal of peptide science : an official publication of the European Peptide Society.

[93]  L. Puglielli,et al.  Ceramide stabilizes beta-site amyloid precursor protein-cleaving enzyme 1 and promotes amyloid beta-peptide biogenesis. , 2003, The Journal of biological chemistry.

[94]  G. Multhaup.  Identification and regulation of the high affinity binding site of the Alzheimer's disease amyloid protein precursor (APP) to glycosaminoglycans. , 1994, Biochimie.